Aseptic abscess syndrome: a case report of a patient achieving remission with both infliximab originator and biosimilar administered at varied intervals
2024

Case Report on Aseptic Abscess Syndrome and Treatment with Infliximab

Sample size: 1 publication Evidence: low

Author Information

Author(s): Ucci Federica Maria, Scrivo Rossana, Alessandri Cristiano, Conti Fabrizio, Priori Roberta

Primary Institution: Sapienza University of Rome

Hypothesis

Can a patient with aseptic abscess syndrome achieve remission using both infliximab originator and biosimilar at varied intervals?

Conclusion

The patient achieved remission from aseptic abscess syndrome after treatment with both infliximab and a biosimilar, although requiring shortened infusion intervals.

Supporting Evidence

  • The patient initially responded to glucocorticoids but experienced flares upon discontinuation.
  • Remission was achieved with a biosimilar TNFα inhibitor after a non-medical switch.
  • The case highlights the challenges in managing a rare condition with limited existing literature.

Takeaway

A woman with a rare disease called aseptic abscess syndrome got better after taking a medicine called infliximab, but she needed to take it more often than usual.

Methodology

The case report details the patient's medical history, treatment with glucocorticoids, and subsequent use of infliximab and a biosimilar.

Potential Biases

Potential bias due to the lack of control group and reliance on a single patient's experience.

Limitations

The study is based on a single case report, limiting generalizability.

Participant Demographics

A 51-year-old woman with no significant medical history prior to the onset of symptoms.

Digital Object Identifier (DOI)

10.3389/fimmu.2024.1454813

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication